The use of intravenous nitroglycerin in cardiovascular disease.
The development of an intravenous form of nitroglycerin has further enhanced the role of nitrates in the therapy of cardiovascular disorders. This new preparation permits prompt initiation of therapy and rapid attainment of high systemic levels; because of its short half-life, rapid dose titration is both feasible and safe. The antianginal effects of intravenous nitroglycerin are useful in the treatment of coronary vasospasm and unstable angina pectoris. Its hemodynamic effects are of benefit in the therapy of congestive heart failure and in the control of peri-operative hypertension. Recent data suggest that, with appropriate monitoring, intravenous nitroglycerin can be safely administered to patients with evolving myocardial infarction to reduce the extent of myocardial damage.
D000788:Angina Pectoris, Variant / Q000188:drug therapy; D006348:Cardiac Surgical Procedures; D002318:Cardiovascular Diseases / Q000188:drug therapy*; D006333:Heart Failure / Q000188:drug therapy; D006801:Humans; D007023:Hypotension, Controlled / Q000379:methods; D007275:Injections, Intravenous; D009203:Myocardial Infarction / Q000188:drug therapy; D005996:Nitroglycerin / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use
D005996:Nitroglycerin